By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Fortress Biotech (Formerly Known As Coronado Biosciences) 

2 Gansevoort Street
9th Floor
New York  New York  10014  U.S.A.
Phone: 781-652-4500 Fax: n/a


Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ: NHLD), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs.




CEO: Lindsay A. Rosenwald

CFO: Lucy Lu


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Fortress Biotech
Symbol: FBIO

Start Up

Company News
Fortress Biotech (FBIO) Forms New Subsidiary, Aevitas Therapeutics, To Develop Novel AAV Gene Therapy Treatments For Complement-Mediated Diseases 8/14/2017 8:13:03 AM
Fortress Biotech (FBIO) Announces Filing Of Provisional Patent Application For Caelum Biosciences' CAEL-101 7/17/2017 10:31:42 AM
Fortress Biotech (FBIO) Announces Appointment Of Lucy Lu, MD, As President And Chief Executive Officer Of Subsidiary Avenue Therapeutics 7/7/2017 7:59:21 AM
Fortress Biotech (FBIO) Announces That Its Subsidiary, Mustang Bio, Enters Into License Agreements With City of Hope For Novel CAR T Immunotherapies 6/5/2017 12:02:48 PM
Fortress Biotech (FBIO) Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon (PTHN) 6/1/2017 11:16:22 AM
Fortress Biotech (FBIO) Reports First Quarter 2017 Financial Results And Recent Corporate Highlights 5/11/2017 1:11:22 PM
Fortress Biotech (FBIO) Announces Final Patient Dosed In Phase IB Trial Of CAEL-101 For The Treatment Of AL Amyloidosis 5/4/2017 10:28:24 AM
Fortress Biotech (CNDO) Forms Cellvation, Taps Forest (FRX), Life Technologies (LIFE) Alum as Interim CEO 11/7/2016 6:51:27 AM
Fortress Biotech (CNDO)'s Avenue Therapeutics Files Form 10 to Go Public 12/30/2015 6:44:18 AM
Fortress Biotech (CNDO) Reports Financial Results For The Third Quarter 2015 Ended September 30, 2015 11/9/2015 8:46:17 AM